Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Cash (2016 - 2025)

Historic Change in Cash for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Change in Cash rose 37467.8% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 32448.93%. This contributed to the annual value of -$3.6 million for FY2024, which is 9936.46% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Change in Cash of $47.6 million as of Q3 2025, which was up 37467.8% from -$15.6 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Change in Cash registered a high of $84.1 million during Q1 2023, and its lowest value of -$565.5 million during Q2 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Change in Cash value was $19.9 million (recorded in 2025), while the average stood at -$11.8 million.
  • The largest annual percentage gain for Ironwood Pharmaceuticals' Change in Cash in the last 5 years was 41444.43% (2023), contrasted with its biggest fall of 53530.32% (2023).
  • Ironwood Pharmaceuticals' Change in Cash (Quarter) stood at $45.9 million in 2021, then soared by 78.87% to $82.0 million in 2022, then plummeted by 123.54% to -$19.3 million in 2023, then soared by 101.8% to $348000.0 in 2024, then surged by 13565.23% to $47.6 million in 2025.
  • Its Change in Cash stands at $47.6 million for Q3 2025, versus -$15.6 million for Q2 2025 and $19.9 million for Q1 2025.